BridgeBio drops 3.74% after selling royalty rights for heart drug Beyonttra

BridgeBio Pharma, Inc. (NASDAQ:BBIO) dropped 3.74% on Monday, closing at $43.18, due to investors processing the sale of royalty rights from heart drug Beyonttra. The company secured $300 million from HealthCare Royalty funds for 60% royalty rights from Beyonttra’s first $500 million sales in Europe. Beyonttra treats transthyretin amyloidosis.

Read more at Yahoo Finance: BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights